Tecan announces OEM agreement with DiaSorin

• Tecan to supply fully automated clinical ELISA platform and various detection instruments for MUREX® product line
• Shipment of first instruments for commercial launch expected in early 2011

Männedorf, Switzerland – January 12, 2011 - The Tecan Group (SIX Swiss Exchange: TECN) today announced an OEM agreement with DiaSorin for the supply of a fully automated clinical ELISA platform and certain detection instruments to be used in conjunction with DiaSorin’s MUREX product line for the diagnosis of HIV, HCV and HBV infections. The OEM agreement covers all countries of the world, excluding the United States of America.

The system is based on Tecan’s reliable Freedom EVOlyzer® clinical ELISA platform with an integrated Tecan Sunrise™ absorbance reader and a HydroFlex™ microplate washer. Additional Tecan detection instruments covered by the agreement include the Infinite® F50 absorbance reader and the ProfiBlot™ 48 instrument for Western Blotting. Tecan will also supply DiaSorin with plastic consumables as an integral part of the validated system. Tecan expects to ship first instruments for the commercial launch to DiaSorin in early 2011. Financial details of the agreement were not disclosed.

In the past, Tecan supplied a first generation fully automated ELISA platform for the MUREX product line to Abbott. In June 2010, DiaSorin completed the acquisition of the MUREX product line from Abbott.

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

For further information
Tecan Group

Martin Brändle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

About DiaSorin
DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.it

For further information please contact:

DiaSorin S.p.A.
Laura Villa
Investor Relations Director
T  +39 02 9647 4567
M +39 348 1511 542
laura.villa@diasorin.it
www.diasorin.it